Soluble E-cadherin Drives Brain Metastasis in Inflammatory Breast Cancer

Area of Science:

• Oncology
• Cancer Metastasis
• Neuro-oncology

Background:

• Inflammatory breast cancer (IBC) frequently metastasizes to the brain.
• E-cadherin plays a role in cell adhesion and cancer progression.
• Soluble E-cadherin (sEcad) is a potential biomarker in metastatic cancers.

Purpose of the Study:

• To investigate the role of soluble E-cadherin (sEcad) in brain metastasis of inflammatory breast cancer (IBC).
• To elucidate the mechanisms by which sEcad promotes brain metastasis.
• To evaluate the therapeutic potential of targeting sEcad-mediated pathways.

Main Methods:

• Analysis of serum sEcad levels in IBC patients.
• In vitro studies on sEcad binding to XIAP and activation of NF-κB signaling.
• In vivo mouse models of IBC brain metastasis.
• Assessment of sEcad-induced reactive astrocytosis and the CXCL1/CXCL8-CXCR2 axis.
• Treatment with a CXCR2 antagonist (CXCR2-IN-1).

Main Results:

• Elevated serum sEcad levels correlate with poor outcomes and increased brain metastases in IBC patients.
• sEcad binds XIAP, activating NF-κB signaling and promoting tumor cell survival and invasion.
• sEcad induces reactive astrocytosis and upregulates CXCR2 on tumor cells.
• Treatment with CXCR2 antagonist CXCR2-IN-1 reduced brain metastatic burden and improved survival in mouse models.

Conclusions:

• sEcad is implicated in driving IBC brain metastasis.
• sEcad promotes brain metastasis through XIAP/NF-κB signaling and by modulating the brain microenvironment via reactive astrocytes and the CXCR2 axis.
• Targeting the CXCR2 axis represents a promising therapeutic strategy for preventing and treating IBC brain metastasis.